Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront

Monte Rosa Therapeutics, Inc.

Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.
$150 million upfront payment; up to $2.1B in development, regulatory, and sales milestones starting at Phase 2.
Monte Rosa completes ongoing Phase 1 study; Novartis handles all subsequent development from Phase 2 onward.
Monte Rosa eligible for tiered royalties on ex-U.S. net sales and 30% U.S. profit/loss share from Phase 3 onward.
Deal validates Monte Rosa's QuEEN discovery engine and extends operational runway; closing subject to HSR clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.